STXS · XBRL financial data

Stereotaxis financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (STXS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	7,799	4,565*	6,880	4,502	9,196	6,340*	7,472	8,798	7,464	8,642*	6,291	7,670
Cost of revenue	3,740	1,827*	2,914	1,189	5,097	3,124*	3,408	4,219	3,363	4,315*	2,497	3,184
Gross profit	4,059	2,738*	3,966	3,313	4,099	3,216*	4,064	4,579	4,101	4,327*	3,794	4,486
Research and development	2,668	2,212*	2,243	2,273	2,454	2,790*	2,350	1,777	2,546	2,710*	2,397	2,390
General and administrative	3,933	3,039*	3,466	3,760	4,838	5,137*	4,495	4,002	5,178	4,174*	4,761	4,069
Total operating expenses	9,698	8,042*	8,712	9,334	10,444	10,843*	9,993	8,556	10,658	9,976*	9,775	9,054
Operating income (loss)	(5,639)	(5,304)*	(4,746)	(6,021)	(6,345)	(7,627)*	(5,929)	(3,977)	(6,557)	(5,649)*	(5,981)	(4,568)
Other income (expense)	0*	3*	—	(3)	5	—	—	(1)	3	0*	(5)	0*
Net income (loss)	(5,369)	(5,040)*	(4,507)	(5,833)	(6,190)	(7,515)*	(5,823)	(3,826)	(6,463)	(5,531)*	(5,861)	(4,468)
Earnings per share, basic USD per share	(0.07)	(0.06)*	(0.06)	(0.07)	(0.08)	(0.09)*	(0.07)	(0.05)	(0.07)	(0.06)*	(0.06)	(0.05)
Earnings per share, diluted USD per share	(0.07)	(0.06)*	(0.06)	(0.07)	(0.08)	(0.09)*	(0.07)	(0.05)	(0.07)	(0.06)*	(0.06)	(0.05)
Weighted average shares, basic thousands of shares	82,469	82,703*	83,476	84,571	85,825	86,836*	87,769	87,952	92,014	95,992*	98,891	100,032
Weighted average shares, diluted thousands of shares	82,469	82,703*	83,476	84,571	85,825	86,836*	87,769	87,952	92,014	95,992*	98,891	100,032

Balance sheet

CSV

Fiscal quarters (STXS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	22,100	19,818	17,633	14,683	10,663	12,217	10,601	6,967	10,506	13,421	14,616	10,491
Short-term investments	—	—	—	—	—	0	—	—	0	0	—	0
Accounts receivable	5,246	3,822	3,953	2,782	7,921	3,824	4,324	4,393	5,333	5,847	5,303	7,549
Inventory	6,788	8,426	8,252	9,284	9,009	8,331	9,812	9,608	10,147	9,567	10,495	12,520
Prepaid and other current assets	855	676	845	842	869	1,848	1,088	936	677	698	1,297	1,111
Total current assets	35,514	33,267	31,208	28,072	28,812	26,439	25,913	21,904	26,663	33,849	36,027	37,987
Property and equipment, net	3,443	3,304	3,164	3,059	3,733	3,573	3,441	3,284	3,156	3,019	2,956	2,881
Right-of-use asset	5,086	4,982	4,876	4,767	5,618	5,483	5,345	5,204	5,059	4,912	4,760	4,658
Goodwill	—	—	—	—	4,494	3,764	3,764	3,764	3,764	3,764	3,764	3,764
Total assets	44,528	41,909	39,452	36,014	50,935	46,724	45,705	41,173	45,587	52,251	54,030	55,582
Accounts payable	3,243	3,190	3,307	4,146	6,403	5,668	6,544	6,730	4,681	4,768	4,823	6,866
Accrued liabilities	3,160	2,972	3,164	2,698	3,376	2,922	2,926	1,731	1,969	2,065	1,478	1,325
Total current liabilities	13,032	13,247	12,852	12,252	20,721	21,602	24,229	20,748	20,370	22,360	23,086	26,797
Lease liability, non-current	5,173	5,062	4,945	4,823	5,583	5,436	5,280	5,122	4,960	4,794	4,618	4,484
Total liabilities	20,230	19,989	19,421	19,250	34,712	35,292	37,529	34,421	34,053	33,530	34,432	38,105
Accumulated deficit	(532,640)	(537,680)	(542,187)	(548,020)	(554,210)	(561,725)	(567,548)	(571,374)	(577,837)	(583,368)	(589,229)	(593,697)
Total stockholders' equity	18,715	16,343	14,567	11,356	10,815	6,080	2,880	1,456	6,266	13,481	14,358	12,243
Total liabilities and equity	44,528	41,909	39,452	36,014	50,935	46,724	45,705	41,173	45,587	52,251	54,030	55,582
Common shares outstanding (cover page) thousands of shares	80,885	82,129	82,643	84,656	84,730	85,980	86,001	90,654	93,325	97,249	97,737	100,202

Cash flows

CSV

Fiscal quarters (STXS's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(5,369)	(5,040)*	(4,507)	(5,833)	(6,190)	(7,515)*	(5,823)	(3,826)	(6,463)	(5,531)*	(5,861)	(4,468)
Stock-based compensation	2,673*	2,636*	2,589	2,538*	2,569*	2,566*	2,535	2,367*	2,503*	2,447*	2,110	1,608*
Net cash from operating activities	(967)*	(2,439)*	(2,346)	(3,088)*	(4,329)*	1,266*	(1,779)	(3,733)*	(4,204)*	(3,969)*	(3,442)	(3,675)*
Net cash from investing activities	(10)*	0*	—	—	98*	(2)*	—	—	0*	(70)*	(79)	(1,145)*
Proceeds from issuing common stock	25*	26*	30	28*	80*	159*	32	34*	7,743*	7,847*	4,853	771*
Proceeds from issuing equity	—	—	—	—	—	—	—	—	—	year only	4,800	700*
Dividends paid	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from financing activities	25*	26*	30	28*	80*	159*	32	34*	7,743*	6,954*	4,716	695*
Net change in cash	(952)*	(2,413)*	(2,316)	(3,082)*	(4,151)*	1,423*	(1,747)	(3,722)*	3,539*	2,915*	1,195	(4,125)*

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	79,753	23,388	(5,663)*	55.1M	14.1 quarters	Q2 FY26 10-QJun 30, 2026
Semler Scientific	10,176	7,491	(32,950)*	15.2M	0.3 quarters	Q3 FY25 10-QSep 30, 2025
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Utah Medical Products	87,528	8,529	1,383*	3.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.